Ipsen SA and Foreseen Technology (Beijing) Co. Ltd. have entered into an exclusive global licensing agreement for FS-001, an antibody-drug conjugate (ADC) that targets a novel tumor-associated antigen highly expressed across a range of solid tumors that was identified through the application of Foreseen’s proprietary proteomic platforms.
N6-Methyladenosine (m6A) is the most widely distributed RNA modification in eukaryotes and its dysregulation has been tied in gastric cancer protumorigenic processes, as well as drug resistance and metastasis. Vir-like m6A methyltransferase associated, also known as KIAA1429, is a crucial regulator of the m6A complex, and thus hypothesized to be involved in the progression of gastric cancer.
Researchers from the Center for Applied Medical Research (CIMA) in Spain have published preclinical data for two new histone deacetylase (HDAC) inhibitors – CM-444 and CM-1758 – being developed for the treatment of acute myeloid leukemia (AML).
Myricx Bio Ltd. has closed the largest series A for a European biotech this year, raising £90 million (US$115.4 million), to take forward antibody-drug conjugates based on novel payload chemistry.
Drug conjugates acting as gonadotropin-releasing hormone (GnRH) receptor ligands have been described in a recent Radionetics Oncology Inc. patent. They are reported to be useful for the diagnosis and treatment of cancer.
Oncopia Therapeutics Inc. has patented proteolysis targeting chimeric (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to a CREB-binding protein (CREBBP; CBP) and/or histone acetyltransferase KAT3B (P300)-targeting moiety through a linker.
As PD-L1 and CD73 are both overexpressed in the tumor microenvironment (TME) and inhibiting CD73 has been shown to enhance anti-PD-L1 efficacy, dual-targeting of PD-L1 and CD73 has emerged as a feasible strategy in the oncolytic field.
Researchers from the University of California San Francisco and Northwestern University recently presented findings from a study that aimed to evaluate the role of lin-28 homolog B (LIN28B), an RNA binding protein expressed in a variety of cancers, in diffuse midline glioma (DMG).
Bolt Biotherapeutics Inc. has designed new antibody-drug conjugates comprising humanized monoclonal antibody trastuzumab targeting HER2 covalently linked to thienoazepine derivatives acting as Toll-like receptor 7 (TLR7) and/or 8 (TLR8) agonists.
Avelos Therapeutics Inc. has discovered new substituted heterocyclic compound derivatives acting as serine/threonine-protein kinase greatwall (MASTL; GWL) inhibitors.
RSS
